The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 27, Issue 12, 2011, Pages 1299-1309

  Marzocchetti, Angela ^a   Schwarz, Jessica ^a   Di Giambenedetto, Simona ^a   Colafigli, Manuela ^a   Bracciale, Laura ^a   Fabbiani, Massimilliano ^a   Fantoni, Massimo ^a   Trecarichi, Enrico ^a   Cauda, Roberto ^a   De Luca, Andrea ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIVIRUS AGENT; APOLIPOPROTEIN E; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY FAT; DNA DETERMINATION; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; GENDER; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; APOLIPOPROTEINS E; CHOLESTEROL, HDL; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82455210401     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0172     Document Type: Article

References (66)

1. Bergersen BM, Schumacher A, Sandvik L, et al.: Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy control. Scand J Infect Dis2006;38:682-689. (Pubitemid 44144728)
2. Estrada V, Martínez-Larrad MT, González-Sánchez JL, et al.: Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metab Clin Exp 2006;55:940-945. (Pubitemid 43902897)
3. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349(21): 1993-2003.
4. Cotte L, Simon A, Partisani M, et al.: Clinical Epidemiology Group from the French Hospital Database. Increased Risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486. (Pubitemid 38393320)
5. Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2003;32:130-139.
6. Blanch J, Rousaud A, Martinez E, et al.: Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004;38:1464-1470. (Pubitemid 38668594)
7. Ammassari A, Antinori A, Cozzi-Lepri A, et al.: Relationship between cART adherence and adipose tissue alterations. J Acquir Immunodefic Syndr 2002;31(Suppl):140-144.
8. Hoffmeyer S, Burk O, von Richter O, et al.: Functional polymorphism of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97(7):3473-3478. (Pubitemid 30183327)
9. Fellay J, Marzolini C, Meaden ER, Back DJ, et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. The Lancet 2002;359:30-36. (Pubitemid 34119193)
10. Negredo E, Ribalta J, Ferré R, et al.: Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIVinfected patients. AIDS 2004;8(5):819-821. (Pubitemid 38535014)
11. Alonso-Villaverde C, Coll B, Gómez F, et al.: The efavirenzinduced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS 2005;19:341-350.
12. Hotamisligil GS, Arner P, Caro JF, et al.: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95(5):2409-2415.
13. Nolan D, Moore C, Castley A, et al.: Tumour necrosis factoralpha gene - 238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003;17(1):121-123. (Pubitemid 36106307)
14. Maher B, Alfirevica A, Vilar FJ, et al.: TNF-a promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002;16:2013-2018. (Pubitemid 35205264)
15. Tarr PE, Taffe P, Bleiber G, et al.: Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipd disorders. J Infect Dis 2005;191(9):1419-1426. (Pubitemid 40563352)
16. Takahashi M, Arita Y, Yamagata K, et al.: Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord 2000;24(7):861-868. (Pubitemid 30449921)
17. Gavrila A, Chan JL, Yiannakouris N, et al.: Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: Cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88(10):4823-4831. (Pubitemid 37357532)
18. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86(5):1930-1935. (Pubitemid 32472900)
19. Samaras K, Gan SK, Peake PW, et al.: Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obesity (Silver Spring) 2009;17(1): 53-59. (Pubitemid 50331903)
20. Hara K, Boutin P, Mori Y, et al.: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51(2):536-540. (Pubitemid 34764814)
21. Menzaghi C, Ercolino T, Di Paola RA, et al.: Haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002;51(7): 2306-2312. (Pubitemid 34729040)
22. Stumvoll M, Tschritter O, Fritsche A, et al.: Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: Interaction with family history of type 2 diabetes. Diabetes 2002;51(1):37-41. (Pubitemid 34517977)
23. Mahley RW and Rall SC: Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
24. Song Y, Stampfer MJ, Liu S, et al.: Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141(2):137-147. (Pubitemid 38937836)
25. Behrens G, Schmidt H.J, Stoll M, et al.: ApoE genotype and protease-inhibitor associated hyperlipidaemia. Lancet 1999; 354(9172):76. (Pubitemid 29304321)
26. Rotger M, Bayard C, Taffé P, et al.: Contribution of genomewide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: A longitudinal study. Circ Cardiovasc Genet 2009;2(6): 621-628.
27. Fauvel J, Bonneta E, Ruidavetsb JB, et al.: An interaction between Apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001;15:2397-2406. (Pubitemid 34014608)
28. Arnedo M, Taffé P, Sahli R, et al.: Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genom 2007;17(9):755-564.
29. Eckel RH: Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989;320:1060-1068. (Pubitemid 19105751)
30. Huang AQ, Hu YH, Zhan SY, et al.: Lipoprotein lipase gene S447X polymorphism modulates the relation between central obesity and serum lipids, a twin study. Int J Obes (Lond) 2006;30(12):1693-1701. (Pubitemid 44863399)
31. Lee J, Tan CS, Chia KS, et al.: The lipoprotein lipase S447X polymorphism and plasma lipids: Interactions with APOE polymorphisms, smoking, and alcohol consumption. J Lipid Res 2004;45:1132-1139. (Pubitemid 38679509)
32. Executive Summary of the Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285. No. 19, special communication.
33. Zanone Poma B, Riva A, Nasi M, et al.: Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008;22(14):1769-1778.
34. Chen CJ, Clark D, Ueda K, et al.: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990;265(1):506-514.
35. Ameyaw MM, Regateiro F, Li T, et al.: MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-221. (Pubitemid 32319871)
36. Li H-Q, Li Z, Liu Y, et al.: Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection. World J Gastroenterol 2005;11(33):5213-5217. (Pubitemid 41410342)
37. Gonzalez-Sanchez, JL, Martinez-Calatrava MJ, Martinez- Larrad MT, et al.: Interaction of the 308G/A promoter polymorphism of the tumor necrosis factor-a gene with single-nucleotide polymorphism 45 of the adiponectin gene: Effect on serum adiponectin concentrations in a Spanish population. Clin Chem 2006;52(1):97-103. (Pubitemid 43032472)
38. Arca M, Campagna F, Montali A, et al.: The common mutations in the lipoprotein lipase gene in Italy: Effects on plasma lipids and angiographically assessed coronary. Atherosclerosis. Clin Genet 2000;58:369-374.
39. Uboldi de Capei MU, Dametto E, Fasano ME, et al.: Genotyping for cytokine polymorphisms: Allele frequencies in the Italian population. Eur J Immunogenet 2003;30(1):5-10. (Pubitemid 36241236)
40. Hosking L, Lumsden S, Lewis K, et al.: Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet 2004;12(5):395-399. (Pubitemid 38660191)
41. Sax PE and Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J AIDS 2004;37(1):1111-1124. (Pubitemid 39166645)
42. Galli M, Veglia F, Angarano G, et al.: Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J AIDS 2003;34(1):58-61. (Pubitemid 37100112)
43. Chan KJ, Harris M, Montessori V, et al.: Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15(2):231-239. (Pubitemid 32142299)
44. Miller J, Carr A, Emery S, et al.: HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia. HIV Med 2003;4(3):293-301. (Pubitemid 36949887)
45. Thiébaut R, Daucourt V, Mercié P, et al.: Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidé- miologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine. Clin Infect Dis 2000;31(6):1482-1487.
46. Ma Q, Brazeau D, Zingman BS, et al.: Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007;8(3):227-235. (Pubitemid 46477734)
47. Launay O, Brendel K, Mentre' F, et al.: Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS 2005;19(18):2127-2131. (Pubitemid 41669001)
48. Winzer R, Langmann P, Zilly M, et al.: No influence of the Pglycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatent. Eur J Med Res 2003;8(12):531-534.
49. Kim RB, Fromm MF, Wandel C, et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294. (Pubitemid 28067324)
50. Jones K, Hoggard PG, Sales SD, et al.: Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001;15(6):675-681. (Pubitemid 32423214)
51. Rendón A, Barrios A, Corral A, et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C/T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006;42(2):291-295. (Pubitemid 43054206)
52. Jones SP, Waitt C, Sutton R, et al.: Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS 2008;22(11):1293-1298.
53. Saillan-Barreau C, Tabbakh O, Chavoin JP, et al.: Drug-specific effect of nelfinavir and stavudine on primary culture of human preadipocytes. JAcquir ImmuneDefic Syndr 2008;48(1):20-25. (Pubitemid 351600856)
54. Fernández-Real JM, Broch M, Ricart W, et al.: Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 1998;47(11):1757-1762. (Pubitemid 28476250)
55. Sethi JK and Hotamisligil GS: The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999;10(1):19-29. (Pubitemid 129505535)
56. Ariza MJ, Sánchez-Chaparro MA, Barón FJ, et al.: Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: Results of the ICARIA genetic sub-study. BMC Med Genet 2010;11:66.
57. Mackevics V, Heid IM, Wagner SA, et al.: The adiponectin gene is associated with adiponectin levels but not with characteristics of the insulin resistance syndrome in healthy Caucasians. Eur J Hum Genet 2006;14(3):349-356.
58. Vigouroux C, Maachi M, Nguyên TH, et al.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17(10):1503-1511. (Pubitemid 36900551)
59. Luo L, Zhang L, Tao M, et al.: Adiponectin and leptin levels in Chinese patients with HIV-related lipodystrophy: A 30- month prospective study. AIDS Res Hum Retroviruses 2009;25(12):1265-1272
60. Sutinen J, Korsheninnikova E, Funahashi T, et al.: Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003;88(4):1907-1910. (Pubitemid 36623422)
61. Jang Y, Lee JH, Chae JS, et al.: Association of the 276G/T polymorphism of the adiponectin gene with cardiovascular disease risk factors in nondiabetic Koreans. Am J Clin Nutr 2005;82(4):760-767. (Pubitemid 43779688)
62. Bernal E, Masiá M, Padilla S, et al.: High-density lipoprotein cholesterol in HIV-infected patients: Evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS 2008; 22(7):569-575. (Pubitemid 352040053)
63. El-Sadr WM, Mullin CM, Carr A, et al.: Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naive cohort. HIV Med 2005;6(2):114-121 (Pubitemid 40425975)
64. Law M, Puls R, Cheng AK, et al.: Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144- week study in antiretroviral-naive adults. Antivir Ther 2007;11:179-186.
65. Guaraldi G, Orlando G, Murri R, et al.: Quality of life and body image in the assessment of psychological impact of lipodystrophy: Validation of the Italian version of assessment of body change and distress questionnaire. Qual Life Res 2006;15(1):173-178. (Pubitemid 43097598)
66. Foulkes AS, Wohl DA, Frank I, et al.: Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 2006;3(3):e52.